Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Cancer Clinical Trial

Official title:

An Open-label, Parallel Group Study to Explore the Pharmacokinetics of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors and Normal or Reduced Hepatic Function According to the Child-Pugh System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00706095
• Other study ID #: E7389-E044-108
• Status: Completed
• Phase: Phase 1
• First received: February 4, 2008
• Last updated: March 21, 2012
• Start date: February 2008
• Est. completion date: April 2010

Study information

• Verified date: March 2012
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: European Union: European Medicines Agency
• Study type: Interventional

Clinical Trial Summary

This is an open-label, three-parallel group pharmacokinetic study. Patients with advanced solid tumors will be assigned to one of three groups to receive I.V. doses of eribulin (E7389). The three groups are: normal hepatic function, mild hepatic impairment (Child-Pugh A) and moderate hepatic impairment (Child-Pugh B) according to the Child-Pugh System for classifying hepatic impairment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: April 2010
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have a histologically or cytologically confirmed advanced solid tumor that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy)

2. Age = 18 years

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.

4. Life expectancy of = 3 months

5. Adequate renal function as evidenced by serum creatinine = 2.0 mg/dL or calculated creatinine clearance = 40 mL/minute (min) per the Cockcroft and Gault formula.

6. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) = 1.5 x 10^9/L, hemoglobin = 10.0 g/dL (a hemoglobin <10.0 g/dL is acceptable if it is corrected by growth factor or transfusion), and platelet count = 100 x 10^9/L

7. Patients willing and able to comply with the study protocol for the duration of the study

8. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Additional Inclusion Criteria for the Group of Patients with No Hepatic Impairment:

• All the general inclusion criteria listed above plus: Normal hepatic function as evidenced by bilirubin = 34 µmol/l (=2.0 mg/dL) and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) =3 times the upper limits of normal (ULN) (in the case of liver metastases =5 x ULN), or in the case of bone metastases, the liver specific alkaline phosphatase =3 times the upper limits of normal (ULN), and in the case of concomitant liver metastases, =5 x ULN.

Additional Inclusion Criteria for the Group of Patients with Hepatic Impairment:

• All the general inclusion criteria listed above plus:

• Mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic dysfunction according to the Child-Pugh scoring system criteria, where patients with laboratory values within normal ranges will not be included in the Child-Pugh A category

• Or, Moderate hepatic dysfunction (Child-Pugh B) according to the Child-Pugh scoring system criteria

Exclusion Criteria:

1. Patients who have received any of the following treatments within the specified period before E7389 treatment start:

1. Chemotherapy, radiation, biological therapy within 3 weeks.

2. Hormonal therapy within 1 week.

3. Any investigational drug within 4 weeks.

2. Patients with any clinically significant laboratory abnormality except for those parameters influenced by hepatic impairment.

3. Patients with severe (Child-Pugh C) hepatic dysfunction according to the Child-Pugh scoring system.

4. Patients with encephalopathy = Grade 1.

5. Patients receiving any drug known to induce or inhibit CYP3A4 activity. Clinically significant drugs are listed in a comprehensive list that can be found at http://medicine/iupui.edu/flockhart/table.htm.

6. Patients, who require therapeutic anti-coagulant therapy other than for line patency with warfarin or related compounds and cannot be changed to heparin-based therapy, are not eligible.

7. Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.

8. Fertile men who are not willing to use contraception or fertile men with a female partner who are not willing to use contraception

9. Severe/uncontrolled intercurrent illness/infection.

10. Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association [NYHA] Grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).

11. Patients with organ allografts requiring immunosuppression (not including blood and blood components transfusions).

12. Patients with known positive HIV status.

13. Patients with brain or subdural metastases are not eligible, unless they are stable and have completed local therapy and have discontinued the use of corticosteroids for this indication for at least four weeks before starting treatment with E7389.

14. Patients with meningeal carcinomatosis.

15. Patients with a hypersensitivity to halichondrin B and/or halichondrin B-like compounds.

16. Patients who participated in a prior E7389 clinical trial.

17. Patients with preexisting neuropathy > Grade 2.

18. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• E7389
E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m^2 for normal hepatic function.
• E7389
E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m^2 for mild hepatic impairment (Child-Pugh A)
• E7389
E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m^2 for moderate hepatic impairment (Child-Pugh B)

Locations

Country	Name	City	State
Netherlands	Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital	Amsterdam
Netherlands	Utrecht Medical Centre	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Inc.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean (SD) Pharmacokinetic (PK) Parameter Area Under Concentration Time Curve From Zero to Infinity (AUC0-oo)		Pre-dose (-0.5h); post-dose at 15 min, 30 min, 60 min, 2 hrs, 4 hrs, 6 hrs, 10 hrs, 24 hrs, 48 hrs, 72hrs, 96 hrs, 120 hrs and 144 hours.	No
Primary	Mean (SD) Pharmacokinetic (PK) Parameter Maximum Observed Plasma Concentration (Cmax)		Pre-dose (-0.5h); post-dose at 15 min, 30 min, 60 min, 2 hrs, 4 hrs, 6 hrs, 10 hrs, 24 hrs, 48 hrs, 72hrs, 96 hrs, 120 hrs and 144 hours.	No
Primary	Best Overall Response Per Response Evaluation Criteria in Solid Tumors (RECIST)	Defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).	throughout the study and up to 30 days after the last dose of study drug	No